Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

RNN $0.73 0.0680 +10.27%
IMNP $3.79 0.2900 +8.29%
MRTX $18.07 1.3200 +7.88%
CBMG $18.40 1.2850 +7.51%
MGNX $20.15 1.3000 +6.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TGTX $8.26 -1.3350 -13.92%
VRML $2.37 -0.1300 -5.20%
GERN $2.59 -0.1300 -4.78%
CNDO $1.64 -0.0600 -3.53%
CTIC $2.66 -0.0800 -2.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Antibody Halts Cancer-Related Wasting Condition

(Dana-Farber Cancer Institute) July 13, 2014 - New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle occurring in about half of all cancer patients, raising their risk of death, according to scientists from Dana-Farber Cancer Institute
read press release 



Young Hispanic Men Face Rising Testicular Cancer Rates

(Reuters Health) July 14, 2014 - Testicular cancer rates are increasing more than three percent per year among young Hispanic men, at a time when rates among non-Hispanic white men are remaining steady, according to a new study.
read article 



FDA Weighs Cancer Risk of Fibroid Removal Devices

(ABC News/Associated Press) July 11, 2014 - Federal health advisers say there is little to no evidence that a popular technique for removing fibroids can be performed without the risk of spreading undetected cancers to other parts of the body.
read article 



Roche Skin Cancer Drug Meets Main Goal in Combination Study

(Reuters) July 14, 2014 - An experimental drug from Roche helped people with an advanced form of skin cancer live longer without their disease worsening when used in combination with another treatment, the Swiss drugmaker said on Monday.
read article 



Some Oncology Practices Report Difficulty Obtaining Paclitaxel

(ASCO in Action) July 11, 2014 - ASCO is hearing that some oncology practices are having difficulty obtaining paclitaxel, although more supply may be on the way from manufacturers.
read article 



The Life Raft Group and Bayer HealthCare Present GIST Awareness Day on Sunday, July 13

(MarketWatch) July 9, 2014 - To raise awareness about gastrointestinal stromal tumors (GIST), the Life Raft Group, a leading GIST advocacy organization, designates Sunday, July 13, 2014 as worldwide GIST Awareness Day, through a presenting sponsorship from Bayer HealthCare.
read article 



FDA Has Free-Speech, Safety Issues to Weigh in Review of ‘Off-Label’ Drug Marketing Rules

(Washington Post) July 9, 2014 - In the long-running conflict between federal regulators and drugmakers over how companies promote their drugs for unapproved uses, the landscape could be shifting, if only in subtle ways, and the outcome could affect doctors and patients alike.
read article (free registration required) 



Questcor Reveals Adverse Events Data for Acthar for First Time

(New York Times) July 10, 2014 - The drug manufacturer, recipient of a $5.6 billion takeover bid, disclosed that almost 5 percent of prescriptions generated reports of ill effects.
read article 



Girl Hoped to Have Been Cured of HIV Has Relapsed

(ABC News/Associated Press) July 10, 2014 - A Mississippi girl born with the AIDS virus and in remission for more than two years despite stopping treatment now shows signs that she still harbors HIV — and therefore is not cured.
read article  



U.S. Senators Ask Gilead to Explain Cost of Sovaldi Hepatitis Drug

(Reuters) July 11, 2014 - Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough treatment for hepatitis C, citing the expense to federal healthcare programs.
read article 



Pietenpol Named to IOM Cancer Policy Forum

(VUMC Reporter) July 10, 2014 - Jennifer Pietenpol, Ph.D., B.F. Byrd Jr. Professor of Oncology and director of Vanderbilt-Ingram Cancer Center, has been named an at-large member of the National Cancer Policy Forum, an advisory group of the Institute of Medicine (IOM) of the National Academies.
read article 



NeoGenomics Expands Next Generation Sequencing Services and Offers 23 Different Profiles for Various Hematologic and Solid Cancers

(NeoGenomics) July 11, 2014 - NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE™ Cancer Profiles based on next-generation sequencing (NGS).
read corporate press release 



ProStrakan Buys Fellow UK Firm Archimedes for £230 Million

(PharmaTimes [UK]) July 11, 2014 - Scotland’s ProStrakan has agreed to buy fellow UK cancer pain specialist Archimedes Pharma for £230 million in cash.
read article 



University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services

(UH Case Medical Center) July 10, 2014 - The U.S. Department of Health and Human Services (HHS) has announced a three-year grant to University Hospitals (UH) Case Medical Center Seidman Cancer Center totaling $4.7 million to support a new national model aimed at improving care for patients with complex cancer.
read press release 



UK Cancer Patients Face Increasing Coverage Restrictions Due to Centralized Cost-Effectiveness Standard, New Report Shows

(PhRMA) July 10, 2014 - New research results announced today quantify the extent to which centralized value assessments by the UK’s National Institute for Health and Care Excellence (NICE) lead to coverage denials and patient access restrictions to new drugs and biologics.
read press release 



Variations in Key Gene Predict Cancer Patients’ Risk for Radiation-Induced Toxicity

(Mount Sinai Hospital) July 8, 2014 - Key genetic variants may affect how cancer patients respond to radiation treatments, according to a study published this week in Nature Genetics.
read press release 



New Drug Active Against Most Aggressive Type of Lung Cancer Cells

(University of Manchester [UK]) July 11, 2014 - Scientists from the Cancer Research UK Manchester Institute teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug – known as AZD3965 - on small cell lung cancer cells.
read article 



Antioxidants Appear to Be Harmful in Cancer Patients

(Medscape Medical News) July 11, 2014 - While alternative health gurus often encourage increasing antioxidants in the diet and the taking of antioxidant nutritional supplements such as beta-carotene, vitamins A, C, and E, and selenium, new research findings suggest that antioxidants could do more harm than good, especially in cancer patients.
read article (free registration required) 



Cancer Cells May Guide Treatment

(Boston Globe) July 11, 2014 - A Boston-based team published proof Thursday that one of the most alluring ideas in cancer care can work: Exceedingly rare tumor cells can be filtered from a patient’s blood sample and used to noninvasively monitor the evolution of cancer and identify the most promising treatments.
read article (free registration required) 



Doctor Quits Uterine-Device Safety Panel Over Conflict

(Wall Street Journal) July 10, 2014 - A member of a panel advising the government on the safety of a medical device that can spread cancer in women stepped down after the U.S. Food and Drug Administration reviewed consulting fees he accepted from a device manufacturer, the agency said Thursday.
read article (paid subscription required) 



Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade)/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma

(Yahoo! Finance) July 9, 2014 - Threshold Pharmaceuticals, Inc. today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade®) and low-dose dexamethasone ("TBorD") in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.
read article 



14 Insanely Important Biotech/Drug Trading Catalysts For the Rest of 2014

(TheStreet) July 10, 2014 - Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
read article 



Health Insurers Are Trying New Payment Models, Study Shows

(New York Times) July 9, 2014 - The sector is spending more than $65 billion a year in new “value-based” payment models, according to a Blue Cross Blue Shield Association study, which looked at 350 programs.
read article 



Celgene's Otezla Misses Mark in Ph III Arthritis Study

(PharmaTimes [UK]) July 9, 2014 - Celgene's psoriatic arthritis drug Otezla (apremilast) has failed to hit targets in a late-stage trial assessing its potential in ankylosing spondylitis, a form of arthritis that affects the spine.
read article 



In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis

(New York Times) July 9, 2014 - An experimental drug for eczema relieved severity of symptoms in 85 percent of those who took it. A drug for psoriasis cut severity of symptoms in as many as 82 percent of those who took it.
read article